CLAIMS

1. 6-Deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (I):



(I)

or a pharmaceutically acceptable salt thereof.

2. 3-Decarboxy-4-epi-3-hydroxymethyl-siastain B represented by the formula (V):



(V)

or a pharmaceutically acceptable salt thereof.

3. 6-Deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (X):



(X)

and a pharmaceutically acceptable salt thereof.

4. A process for the production of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (I):



(I)

according to claim 1, characterized in that the process comprises:

eliminating the *N*-acetyl group from an *N*-protected or unprotected-4,5-O-protected-3-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (II):



(II)

wherein R^1 is a hydrogen atom or an imino-protecting group, X^1 and X^2 each are a monovalent hydroxyl-protecting group, or both X^1 and X^2 together denote a divalent hydroxyl-protecting group, to produce an *N*-protected or unprotected-4,5-O-protected-3-hydroxymethyl-de-*N*-acetyl-3-decarboxy-siastatin B represented by the general formula (III):



(III)

wherein R^1, X^1 and X^2 have the same meanings as above;

trifluoroacetylating the free amino group of the compound of the formula (III), to produce an *N*-protected or unprotected-4,5-O-protected-6-deacetamido-3-hydroxymethyl-6-trifluoroacetamido-3-decarboxy-siastatin B represented by the

general formula (IV):



(IV)

wherein R^1, X^1 and X^2 have the same meanings as above;

and then eliminating the imino-protecting group (R^1) if present, and eliminating the hydroxyl-protecting groups (X^1 and X^2) from the compound of the formula (IV).

5. A process for the production of 3-decarboxy-4-epi-3-hydroxymethyl-siastain B represented by the formula (V):



(V)

according to claim 2, characterized in that the process comprises:

eliminating the hydroxyl-protecting groups (X^1 and X^2) from an *N*-protected or unprotected-4,5-O-protected-3-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (II):



(II)

wherein R^1 is a hydrogen atom or an imino-protecting group, and X^1 and X^2 each are a monovalent hydroxyl-protecting group,

or both X^1 and X^2 together denote a divalent hydroxyl-protecting group, to produce an *N*-protected or unprotected-3-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VI):



(VI)

wherein R^1 has the same meanings as above;

protecting both of the hydroxyl group at 3-position and the free hydroxyl group at 5-position of the compound of the formula (VI), to produce an *N*-protected or unprotected-5-O-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VII):



(VII)

wherein R^1 is a hydrogen atom or an imino-protecting group, X^3 and X^4 each denote a hydroxyl-protecting group;

oxidizing the hydroxyl group at 4-position of the compound of the formula (VII), to produce an *N*-protected or unprotected-4-keto-5-O-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (VIII):



(VIII)

wherein R^1, X^3 and X^4 have the same meanings as above;

reducing the keto group at 4-position of the compound of the formula (VIII), to produce an *N*-protected or unprotected-4-epi-5-O-protected-3-protected-hydroxymethyl-3-decarboxy-siastatin B represented by the general formula (IX):



(IX)

wherein R^1, X^3 and X^4 have the same meanings as above;

and then eliminating the imino-protecting group (R^1) if present, and eliminating the hydroxyl-protecting groups (X^3 and X^4) from the compound of the formula (IX).

6. A process for the production of 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B represented by the formula (X):



(X)

according to claim 3, characterized in that the process comprises:

providing by the process according to claim 4, an *N*-protected or unprotected-4,5-O-protected-6-deacetamido-3-hydroxymethyl—6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (IV):



(IV)

wherein R^1 is a hydrogen atom or an imino-protecting group, X^1 and X^2 each are a hydroxyl-protecting group, or both X^1 and X^2 together denote a divalent hydroxyl-protecting group;

eliminating the hydroxyl-protecting groups (X^1 and X^2) from the compound of the formula (IV), to produce an *N*-protected or unprotected-6-deacetamido-3-hydroxymethyl—6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XI):



(XI)

wherein R^1 has the same meaning as above;

protecting both of the hydroxyl group at 3-position and the free hydroxyl group at 5-position of the compound of the formula (XI), to produce an *N*-protected or unprotected-5-O-ptotected-6-deacetamido-3-protected hydroxymethyl—6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XII):



(XII)

wherein R^1 is a hydrogen atom or an imino-protecting group, X^5 and X^6 each are a hydroxyl-protecting group;

oxidizing the hydroxyl group at 4-position of the compound of the formula (XII), to produce an *N*-protected or unprotected-5-O-ptotected-4-keto-6-deacetamido-3-protected hydroxymethyl—6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XIII):



(XIII)

wherein R^1, X^5 and X^6 have the same meanings as above;

reducing the keto group at 4-position of the compound of the formula (XIII), to produce an *N*-protected or unprotected-5-O-ptotected-4-epi-6-deacetamido-3-protected-hydroxymethyl—6-trifluoroacetamido-3-decarboxy-siastatin B represented by the general formula (XIV):



(XIV)

wherein R^1, X^5 and X^6 have the same meanings as above;

and then eliminating the imino-protecting group (R^1) if

present, and eliminating the hydroxyl-protecting groups (X^5 and X^6) from the compound of the formula (XIV).

7. A pharmaceutical composition comprising as an active ingredient 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (I) as claimed in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (X) as claimed in Claim 3, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

8. A pharmaceutical composition according to claim 7, which is used as an anticancer agent, an antidiabetic agent or an antiobestic agent.

9. A glycosidase inhibitor consisting of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (I) as claimed in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of by the formula (X) as claimed in Claim 3, or a pharmaceutically acceptable salt thereof.

10. Use of 6-deacetamido-3-decarboxy-3-hydroxymethyl-6-trifluoroacetamido-siastain B of the formula (I) as claimed in Claim 1, or 3-decarboxy-4-epi-3-hydroxymethyl-siastain B of the formula (V) as claimed in Claim 2, or 6-deacetamido-3-decarboxy-4-epi-3-hydroxymethyl-6-trifluoroacetamido-siastain B of by the formula (X) as claimed in Claim 3, or a pharmaceutically acceptable salt thereof, in the manufacture

of a pharmaceutical composition.